餐后高血糖和心血管危險因素-資料下載頁
2025-05-26 22:09本頁面
【正文】 ostprandial hyperglycaemia decreases the risk of diabetes and CVD STOP NIDDM Acarbose treatment resulted in a ? Relative risk reduction of 25% for the development of diabetes (p=)1 ? Relative risk reduction of 36% using two consecutive OGTTs (p=)1 ? 30% increase in the incidence of normal glucose tolerance (p)2 ? Statistically significant reduction in the risk of – hypertension – myocardial infarction – any cardiovascular event CVD: cardiovascular disease, OGTT: oral glucose tolerance test 1. Chiasson JL, et al. Diabetologia 2022。45(Suppl. 2):A104. 2. Bayer AG, data on file 2022. Chinese studies support the efficacy of acarbose in patients with IGT NGT IGT Diabetes Control (n=83) Diet and exercise (n=60) Metformin (n=88) Acarbose (n=88) Percentage of patients IGT: impaired glucose tolerance, NGT: normal glucose tolerance Wenying Y, et al. Chin J Endocrinol Metab 2022。17:131–6. Study group An emerging algorithm to manage IGT ? Development of evidencebased systems to identify those with IGT at most risk of diabetes ? Lifestyle intervention as firstline therapy for highrisk population ? Pharmacotherapy for those who are not able to attain stable glycaemia with lifestyle intervention ? Pharmacotherapy following lifestyle intervention failure is supported by the International Diabetes Federation IGT: impaired glucose tolerance Conclusions ? Management of the diabetes epidemic is an urgent global priority ? IGT is an appropriate target for intervention to prevent diabetes ? Acarbose has a proven record for safe, longterm management of postprandial hyperglycaemia ? Acarbose is proven to reduce the risk of diabetes and cardiovascular disease ? STOPNIDDM results suggest that acarbose can reduce the burden that type 2 diabetes places on individuals and society IGT: impaired glucose tolerance, STOPNIDDM: Study to Prevent Noninsulin Dependent Diabetes Mellitu
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1